Size and donor disparity influence IOP GAT

Article

Graft size and donor-recipient disparity influence IOP measured with the Goldmann applanation tonometer (IOP GAT) after penetrating keratoplasty (PKP).

Larger grafts and greater donor-recipient disparity are factors influencing IOP measured with the Goldmann applanation tonometer (IOP GAT) after penetrating keratoplasty (PKP), according to a paper in the journal Cornea.

Dr S. Feizi et al., Ophthalmic Research Centre, Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, conducted a cross-sectional study on 34 eyes of 34 keratoconus patients who had experienced penetrating keratoplasty (PKP).

At least six months postoperatively corneal hysteresis (CH), corneal resistance factor (CRF) and cornea-compensated intraocular pressure were measured. The independent t-test was used to compare two groups of donor-recipient disparity. Multivariate regression analysis was employed to assess the correlation of donor trephine size and central graft thickness (CGT) with the ocular response analyzer (ORA). The factors influencing IOP measured with the IOP GAT after PKP were identified using multiple regression analysis.

The findings revealed that mean CGT, CH and CRF were 564.7 ± 36.9 μm, 10.1 ± 2.1 mmHg, and 10.0 ± 2.3 mmHg, respectively. CH and CRF were positively correlated with donor trephine size and CGT, with significant values being observed in the 0.5 mm disparity group, opposed to the 0.25 mm disparity group.

The journal abstract can be found here

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.